IPSC (Century Therapeutics) Total Stockholders Equity : $161.36 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics Total Stockholders Equity?

Century Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $161.36 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Century Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $1.88. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Century Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.33.

Century Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Century Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Total Stockholders Equity Chart

Century Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

-106.41

396.24

302.74

184.75

161.36

Century Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															184.75	177.88	222.10	195.69	161.36

Century Therapeutics (NAS:IPSC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Century Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(161.362	-	0)	/	85.836
	=	1.88

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Century Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.87	+	48.96)	/	161.362
	=	0.33

Century Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Century Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104

Website

https://www.centurytx.com

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Executives

Adrienne Farid	officer: Chief Operations Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Gregory Russotti	officer: Chief Technology Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr	officer: VP of Finance and Operations	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Daphne Quimi	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Luis Borges	officer: Chief Scientific Officer	TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez	director	ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva	director	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky	officer: President of R&D	C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Osvaldo Flores	officer: Chief Executive Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104